• Q2 EBITDA of ~$1.0m
• 1H26 EBITDA of ~$1.48m
• Eighth consecutive quarter of positive EBITDA

Biome Australia Limited (ASX: BIO), a leading microbiome health company, has delivered its best quarterly result to date with sales revenue of $6.5m, representing growth of 41% on the prior corresponding period. The company has now achieved rolling 12-month sales revenue of ~$22m. Biome has also delivered EBITDA of ~$1.0m in Q2, representing the company's eighth consecutive quarter of positive EBITDA, and taking 1H26 EBITDA to ~$1.48m. Customer receipts were $6.2m, up 43% on the prior corresponding period. Combined with the FY25 R&D rebate of $657k received in the quarter, Biome generated net operating cash inflow of ~$1.24m. The company repaid $722k into its working capital facilities during the quarter, reflecting strong cash generation. Biome maintained its gross margin above 61% for Q2 FY26.

Biome expects an increasing proportion of revenue to flow through to earnings and cash generation as revenue continues to grow.

Biome remains focused on expanding its international footprint and strengthening its position as Australia's leading practitioner-only probiotic company.